CORPORATE PRESENTATION January 2025 FORWARD LOOKING STATEMENTS 2 2025 Protara Therapeutics. All Rights Reserved - Do Not Copy or Distribute Statements contained in this presentation regarding matters that are not histori
Monday, January 13, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Protara Therapeutics has released a corporate presentation detailing future strategies and product developments, including TARA-002 for conditions like non-muscle invasive bladder cancer and lymphatic malformations. The document outlines the company's focus on innovating therapies that cater to specific medical needs, including a phospholipid substrate replacement therapy for patients reliant on parenteral support. This presentation appears to set the stage for advancements in their therapeutic pipeline for 2025.
Price reaction · baseline $5.56 (2025-01-10 close) · clean, no other TARA news in the window
day 0 close · peak
-4.5%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+147%
120-day peak, hindsight
Typical move
11.7%
average across 4 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
Choline Chloride
Phase 2 · Choline Deficiency
Full Press Release Details
CORPORATE PRESENTATION January 2025
TARA - 002 Lyophilized, Inactivated Group A Streptococcus pyogenes
TARA - 002 Non - Muscle Invasive Bladder Cancer
IV CHOLINE CHLORIDE Phospholipid substrate replacement therapy for patients dependent on parenteral support (PS)
TARA - 002 Lymphatic Malformations (LMs)
Frequently Asked Questions
What is TARA - 002?
TARA - 002 is a lyophilized, inactivated vaccine targeting Group A Streptococcus pyogenes.
What conditions does TARA - 002 address?
TARA - 002 is indicated for non-muscle invasive bladder cancer and lymphatic malformations.
What is the role of IV Choline Chloride?
IV Choline Chloride is a phospholipid substrate replacement therapy for parenteral support patients.